Aikya Investment Management Ltd Boosts Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Aikya Investment Management Ltd boosted its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 416.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,610,503 shares of the company’s stock after acquiring an additional 4,523,303 shares during the quarter. Dr. Reddy’s Laboratories accounts for 36.9% of Aikya Investment Management Ltd’s portfolio, making the stock its 2nd largest position. Aikya Investment Management Ltd owned approximately 0.67% of Dr. Reddy’s Laboratories worth $88,590,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. lifted its position in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares in the last quarter. Fisher Asset Management LLC lifted its position in Dr. Reddy’s Laboratories by 402.5% in the 4th quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock valued at $38,981,000 after acquiring an additional 1,977,419 shares in the last quarter. State Street Corp lifted its position in Dr. Reddy’s Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after buying an additional 16,641 shares in the last quarter. Mondrian Investment Partners LTD lifted its position in Dr. Reddy’s Laboratories by 356.7% during the 4th quarter. Mondrian Investment Partners LTD now owns 648,813 shares of the company’s stock worth $10,245,000 after buying an additional 506,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock worth $8,373,000 after buying an additional 427,573 shares in the last quarter. 3.85% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Trading Up 1.1 %

Shares of NYSE:RDY opened at $13.59 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company’s 50-day moving average price is $13.69 and its two-hundred day moving average price is $14.73. The stock has a market capitalization of $11.34 billion, a PE ratio of 21.63 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a one year low of $12.50 and a one year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.